Flare-up reaction in the inoculation drug sites by glatiramer acetate: First case described  by Sánchez-González, María-José et al.
lable at ScienceDirect
Allergology International 65 (2016) 469e471Contents lists avaiAllergology International
journal homepage: ht tp: / /www.elsevier .com/locate/al i tLetter to the EditorFlare-up reaction in the inoculation drug sites by glatiramer acetate: First
case describedDear Editor,
Glatiramer acetate (GA) (Copaxone™) is an immunomodulatory
drug used in multiple sclerosis (MS) to reduce the frequency of re-
lapses.1,2 It represents a safe treatment option with mild side ef-
fects. The pre-ﬁlled syringe contains 20 mg of GA and mannitol
as excipient. GA is composed of the acetate salts of synthetic poly-
peptides containing L-glutamic acid, L-alanine, L-tyrosine and L-
lysine, and may work as a decoy for the immune system.1,2 There
are described cases of hypersensitivity to GA as contact dermatitis,
immediate and delayed exanthema and anaphylaxis, with positive
skin tests in some of the cases.2e4 Flare-up reactions are character-
ized by the reactivation of previously positive intradermal tests
(IDT) or skin-prick-tests (SPT) elicited by patch testing or after sys-
temic provocationwith an allergen.5 A case of ﬂare-up reaction dur-
ing provocation test with GA has been described in the skin test
sites.1 To our knowledge, we illustrate the ﬁrst case of a patient
with a ﬂare-up reaction with GA in the inoculation drug sites.
A 37-year-old woman, diagnosed with remittenterecurrent MS
and no history of atopic diseases is presented. She started treat-
ment with subcutaneous injections of Copaxone™ 20 mg/day.
From the ﬁrst dose she immediately had a local erythema and
inﬂammation of 2e3 cm along with pruritus in the injection site,
disappearing spontaneously within 2e3 h. The eleventh day of
treatment, 12 h after the GA administration, she displayed ery-
thema, inﬂammation and pruritus in the gluteal area, arms,
abdomen and legs, with no high fever detected, matching with
the places where the patient had been administering herself the
drug the preceding days. She took dexchlorpheniramine for two
days and was referred to our outpatient clinic.
We observed persistent hot and erythematous plaques with
painful subcutaneous nodules of 2e3 cm in each point of GA inoc-
ulation (Fig. 1A, B), we prescribed a treatment with oral antihista-
mines, topical corticosteroids and we recommended her to
discontinue GA. Besides, a biopsy was obtained from the abdomen
(Fig. 1A). One month later, the lesions disappeared without any re-
sidual lipoatrophy. We performed SPT and IDT on the volar side of
the forearm with immediate, late and delayed lectures 12, 24 and
72 h later, either with GA and mannitol. The SPT with GA was
made at a concentration of 20 mg/ml (1:1) and with mannitol at
200 mg/ml (1:1). The IDTs were carried out at 0.02 mg/ml (1/
1000) and 0.2 mg/ml (1/100) with GA and at 2 mg/ml (1/100)
and 20 mg/ml (1/10) with mannitol. We obtained negative results
for mannitol and a negative SPT and IDT of 0.02 mg/ml for GA.Peer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).However, we found an immediate positive result for GA with IDT
of 0.2 mg/ml which remained positive for 4 days (Fig. 1C). The cuta-
neous testing with the described concentrations were negative in
two non-atopic and two atopic controls.
The biopsy of the lesions showed a lobular panniculitis with
lymphocytic venulitis and a signiﬁcant eosinophilic inﬁltration in
adjacent lobules and hypodermis, as well as thickening and inﬂam-
mation of the septum (Fig. 1DeF). The patient's hemogram was
normal with 190 eosinophils/mm3 (3.4%). Also, in order to clarify
the real involvement of this drug as the responsible of this unique
clinical case, we performed a lymphocyte transformation test (LTT)
to our patient and three sex- and age-matched controls, tolerating
Copaxone™. The patient stimulation index (SI) was higher than the
controls, for different concentrations of GA, being positive (SI > 2),6
in two concentrations (10 and 5 mg/ml) (Table 1) despite the fact
that the patient had started treatment with dimethyl fumarate
(DMF) after we made the skin tests and before we performed the
LTT. DMF has immunosuppressive and immunomodulatory activity,
and GA just immunomodulatory activity. These actions of the drugs
can explain the low SI in the patient, whether positive or not.
Therefore, we diagnosed our patient of ﬂare-up reaction triggered
by GA. In our experience, a positive IDT-result at a concentration
of 0.2 mg/ml does not seem irritating as previously reported.7
GA has the most favorable adverse effect proﬁle compared with
the other therapeutic options available for MS. The most common
adverse effect of GA is a skin reaction at the injection site. In this
immediate-type local reaction an IgE-mediated mechanism is
probably involved.7 It is also frequent, for approximately 20%e
60% of the patients, to have pain, inﬂammation and induration at
the injection site; these symptoms spontaneously disappear within
hours or a few days. Up to 30% of patients have swelling at the in-
jection site of GA, which ceases within minutes or hours. Subse-
quently, over time lipoatrophy can appear, and near 10% of
patients have experienced at least one immediate-type systemic
reaction.8
On the other hand, localized panniculitis at the sites of subcu-
taneous injections of GA for treatment of MS are considered a
rare but distinctive side effect of this therapy, it is also said that it
is underdiagnosed, appearing in up to 40% of the patients including
those with lipoatrophy and no demonstrated panniculitis.9,10 The
histopathologic pattern of these lesions consists of a mostly lobular
panniculitis, with histiocytes and T lymphocytes in the fat lobule
and thickened septa with scattered lymphoid follicles, which are
mostly composed of B lymphocytes.1 The clinical and histopatho-
logical characteristics of drug-induced panniculitis are identical to
others caused by different agents. All these cases were diagnosedvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. A, B) Inoculation plaques on abdomen (biopsy taken from the bottom lesion) (A) and right arm and thigh (B); C) positive IDT of 0.2 mg/ml of glatiramer acetate; D) venous
blood vessel with venulitis and a signiﬁcant eosinophilic inﬂammatory inﬁltrate in adjacent lobules in hypodermis (hematoxylin and eosin stain, original magniﬁcation 40); E)
venous blood vessel with venulitis (elastica van Gieson stain, original magniﬁcation 20); F) eosinophilic inﬁltration in hypodermis, septum and adjacent lobule (hematoxylin and
eosin stain, original magniﬁcation 10).
Table 1
Lymphocyte transformation test (LTT).
Glatiramer acetate Stimulation index (SI)
Case Control #1 Control #2 Control #3
25 mg/ml 1.83 0.81 1.46 nd
10 mg/ml 2.35 1.29 1.80 0.86
5 mg/ml 2.51 1.62 1.34 0.91
1 mg/ml 1.27 0.93 0.86 0.91
0.5 mg/ml 1.75 0.84 0.87 nd
nd, Not done.
Letter to the Editor / Allergology International 65 (2016) 469e471470according to a concordant history of drug intake and clinical
improvement after drug withdrawal. Drug-induced lobular and
mixed panniculitis, including eosinophilic panniculitis, have been
rarely described. Our patient did not have a residual lipoatrophy
and the pathological study of the biopsy illustrated an eosinophilic
panniculitis caused by a ﬂare-up reaction after repeated doses of GA
(Fig. 1DeF).
To the best of our knowledge, we herein report the ﬁrst case of
allergic reaction to GAmanifested as a ﬂare-up reaction in the inoc-
ulation drug sites after treatment reported. This exceptional case
has been conﬁrmed either by cutaneous, histopathological and
serological studies. Further investigation must be carried out inorder to clarify its clinical relevance owing to the potential severity
of reactions which GA may cause.Acknowledgments
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